Limei Ma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Limei Ma has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Chao Yu
Chongqing Medical University
8 shared publications Peng Xiang
College of Pharmacy Chongqing Medical University Chongqing China
5 shared publicationsWanping Zhang
College of Pharmacy, Chongqing Medical University, Chongqing, China
4 shared publicationsJin Lei
Chongqing Key Research Laboratory of Drug Metabolism, College of Pharmacy, Chongqing Medical University, Chongqing, China
3 shared publicationsJun Zhang
Institute of Life Sciences, Chongqing Medical University, Chongqing, China
3 shared publicationsLe Chen
College of Pharmacy Chongqing Medical University Chongqing China
3 shared publications
Latest Publications
- Open Access
- 12 May 2026
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 30 (9) , e71169
Sialidase Neu3 Induced Sialic Acid Disorder and Promoted Vascular Endothelial Injury Through Transcription Factor SP3
Atherosclerotic cardiovascular disease is still a major cause for the increasing mortality worldwide. The elevated metabolite N‐acetylneuraminic acid (Neu5Ac) was considered one of the important risk factors responsible for the initiation of endothelial impairment, then participated in atherosclerosis progression. However, the reason for inducing Neu5Ac accumulation as well as its underlying mechanism remains unclear. Here, we applied human umbilical vein endothelial cells (HUVECs) and ApoE −/− mice to investigate the key genes responsible for Neu5Ac accumulation as well as its regulation mechanism. We found that tumour necrosis factor alpha (TNF‐α) could induce Neu5Ac metabolism disorder and increase Neu5Ac level, accompanied by the increasing levels of inflammatory markers in HUVECs. Further, we found that sialidase NEU3 was significantly up‐regulated, accompanied by Neu5Ac accumulation. NEU3 siRNA in HUVECs could significantly reduce Neu5Ac levels and alleviate endothelial inflammation. In contrast, the addition of exogenous Neu5Ac reversed such phenomenon. Furthermore, we noted that NEU3 was highly expressed in atherosclerotic plaques from ApoE −/− mice as well as atherosclerotic patient tissues. Mechanically, we found that the transcription factor specificity protein 3 (SP3) was activated in HUVECs, responsible for Neu5Ac metabolism disorder. While RNA interference of SP3 could decrease NEU3 mRNA level and reduce endothelial inflammatory injury, indicating that SP3 might be the upstream regulatory factor of NEU3. Together, these findings identified the key role of NEU3 in regulating Neu5Ac metabolism associated with endothelial function, as well as its potential regulation mechanism. Targeting SP3/NEU3 seems to be a potential therapeutic strategy for such diseases with Neu5Ac accumulation like atherosclerosis (AS).
- 12 May 2026
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 30 (9) , e71169
Open AccessSialidase Neu3 Induced Sialic Acid Disorder and Promoted Vascular Endothelial Injury Through Transcription Factor SP3
Atherosclerotic cardiovascular disease is still a major cause for the increasing mortality worldwide. The elevated metabolite N‐acetylneuraminic acid (Neu5Ac) was considered one of the important risk factors responsible for the initiation of endothelial impairment, then participated in atherosclerosis progression. However, the reason for inducing Neu5Ac accumulation as well as its underlying mechanism remains unclear. Here, we applied human umbilical vein endothelial cells (HUVECs) and ApoE −/− mice to investigate the key genes responsible for Neu5Ac accumulation as well as its regulation mechanism. We found that tumour necrosis factor alpha (TNF‐α) could induce Neu5Ac metabolism disorder and increase Neu5Ac level, accompanied by the increasing levels of inflammatory markers in HUVECs. Further, we found that sialidase NEU3 was significantly up‐regulated, accompanied by Neu5Ac accumulation. NEU3 siRNA in HUVECs could significantly reduce Neu5Ac levels and alleviate endothelial inflammation. In contrast, the addition of exogenous Neu5Ac reversed such phenomenon. Furthermore, we noted that NEU3 was highly expressed in atherosclerotic plaques from ApoE −/− mice as well as atherosclerotic patient tissues. Mechanically, we found that the transcription factor specificity protein 3 (SP3) was activated in HUVECs, responsible for Neu5Ac metabolism disorder. While RNA interference of SP3 could decrease NEU3 mRNA level and reduce endothelial inflammatory injury, indicating that SP3 might be the upstream regulatory factor of NEU3. Together, these findings identified the key role of NEU3 in regulating Neu5Ac metabolism associated with endothelial function, as well as its potential regulation mechanism. Targeting SP3/NEU3 seems to be a potential therapeutic strategy for such diseases with Neu5Ac accumulation like atherosclerosis (AS).
- Open Access
- 13 November 2024
- Published by Springer Nature in Cell Death Discovery
- Vol. 10 (1) , 1-16
N-Acetylneuraminic acid triggers endothelial pyroptosis and promotes atherosclerosis progression via GLS2-mediated glutaminolysis pathway
Vascular endothelial injury initiates atherosclerosis (AS) progression. N-Acetylneuraminic acid (Neu5Ac) metabolic disorder was found to intensify endothelial mitochondrial damage. And GLS2-associated glutaminolysis disorder contributed to mitochondrial dysfunction. However, mechanisms underlying Neu5Ac-associated mitochondrial dysfunction as well as its association with GLS2 remains unclear. In this study, we constructed GLS2−/−ApoE−/− mice by using HBLV-GLS2 shRNA injection. And methods like immunofluorescence, western blotting, transmission electron microscopy were applied to detect profiles of endothelial injury and AS progression both in vivo and in vitro. We demonstrated that Neu5Ac accumulation increased GLS2 expression and promoted glutaminolysis disorder, which further induced endothelial mitochondrial dysfunction via a pyroptosis-dependent pathway in vivo and in vitro. Mechanically, Neu5Ac interacted with SIRT3 and led to FOXO3a deacetylation and phosphorylation, further facilitated c-Myc antagonism and ultimately increased GLS2 levels. Inhibition of GLS2 could improve mitochondrial function and mitigate pyroptosis process. In addition, blocking Neu5Ac production using neuraminidases (NEUs) inhibitor could rescue endothelial damage and alleviate AS development in ApoE−/− mice. These findings proposed that Neu5Ac induced GLS2-mediated glutaminolysis disorder and then promoted mitochondrial dysfunction in a pyroptosis-dependent pathway. Targeting GLS2 or inhibiting Neu5Ac production could prevent AS progression.
- 13 November 2024
- Published by Springer Nature in Cell Death Discovery
- Vol. 10 (1) , 1-16
Open AccessN-Acetylneuraminic acid triggers endothelial pyroptosis and promotes atherosclerosis progression via GLS2-mediated glutaminolysis pathway
Vascular endothelial injury initiates atherosclerosis (AS) progression. N-Acetylneuraminic acid (Neu5Ac) metabolic disorder was found to intensify endothelial mitochondrial damage. And GLS2-associated glutaminolysis disorder contributed to mitochondrial dysfunction. However, mechanisms underlying Neu5Ac-associated mitochondrial dysfunction as well as its association with GLS2 remains unclear. In this study, we constructed GLS2−/−ApoE−/− mice by using HBLV-GLS2 shRNA injection. And methods like immunofluorescence, western blotting, transmission electron microscopy were applied to detect profiles of endothelial injury and AS progression both in vivo and in vitro. We demonstrated that Neu5Ac accumulation increased GLS2 expression and promoted glutaminolysis disorder, which further induced endothelial mitochondrial dysfunction via a pyroptosis-dependent pathway in vivo and in vitro. Mechanically, Neu5Ac interacted with SIRT3 and led to FOXO3a deacetylation and phosphorylation, further facilitated c-Myc antagonism and ultimately increased GLS2 levels. Inhibition of GLS2 could improve mitochondrial function and mitigate pyroptosis process. In addition, blocking Neu5Ac production using neuraminidases (NEUs) inhibitor could rescue endothelial damage and alleviate AS development in ApoE−/− mice. These findings proposed that Neu5Ac induced GLS2-mediated glutaminolysis disorder and then promoted mitochondrial dysfunction in a pyroptosis-dependent pathway. Targeting GLS2 or inhibiting Neu5Ac production could prevent AS progression.
- 14 July 2024
- Published by Elsevier in Mechanisms of Ageing and Development
- Vol. 221, 111962
REDD1 knockdown ameliorates endothelial cell senescence through repressing TXNIP-mediated oxidative stress
- 14 July 2024
- Published by Elsevier in Mechanisms of Ageing and Development
- Vol. 221, 111962
REDD1 knockdown ameliorates endothelial cell senescence through repressing TXNIP-mediated oxidative stress
- 11 October 2023
- Published by Wiley in IUBMB Life
- Vol. 76 (3) , 161-178
N‐acetylneuraminic acid modulates SQSTM1/p62 sialyation‐mediated ubiquitination degradation contributing to vascular endothelium dysfunction in experimental atherosclerosis mice
Sialic acid (SIA) has been reported to be a risk factor for atherosclerosis (AS) due to its high plasma levels in such patients. However, the effect of increasing SIA in circulation on endothelial function during AS progression remains unclear. In the present study, ApoE(-/-) mice and endothelial cells line (HUVEC cells) were applied to investigate the effect of SIA on AS progression and its potential molecular mechanism. In vivo, mice were injected intraperitoneally with Neu5Ac (main form of SIA) to keep high-level SIA in circulation. ORO, H&E, and Masson staining were applied to detect the plaque progression. In vitro, HUVECs were treated with Neu5Ac at different times, CCK-8, RT-PCR, western blot, and immunoprecipitation methods were used to analyze its effects on endothelial function and the potential involved mechanism. Results from the present study showed that high plasma levels of Neu5Ac in ApoE(-/-) mice could aggravate the plaque areas as well as increase necrotic core areas and collagen fiber contents. Remarkably, Neu5Ac levels in circulation displayed a positive correlation with AS plaque areas. Furthermore, results from HUVECs showed that Neu5Ac inhibited cells viability in a time/dose-dependent manner, by then induced the activation of inflammation makers such as ICAM-1 and IL-1 beta. Mechanism study showed that the activation of excessive autophagy medicated by SQSTM1/p62 displayed an important role in endothelium inflammatory injury. Neu5Ac could modify SQSTM1/p62 as a sialylation protein, and then increase its level with ubiquitin binding, further inducing ubiquitination degradation and being involved in the excessive autophagy pathway. Inhibition of sialylation by P-3Fax-Neu5Ac, a sialyltransferase inhibitor, reduced the binding of SQSTM1/p62 to ubiquitin. Together, these findings indicated that Neu5Ac increased SQSTM1/p62-ubiquitin binding through sialylation modification, thereby inducing excessive autophagy and subsequent endothelial injury. Inhibition of SQSTM1/p62 sialylation might be a potential strategy for preventing such disease with high levels of Neu5Ac in circulation.
- 11 October 2023
- Published by Wiley in IUBMB Life
- Vol. 76 (3) , 161-178
N‐acetylneuraminic acid modulates SQSTM1/p62 sialyation‐mediated ubiquitination degradation contributing to vascular endothelium dysfunction in experimental atherosclerosis mice
Sialic acid (SIA) has been reported to be a risk factor for atherosclerosis (AS) due to its high plasma levels in such patients. However, the effect of increasing SIA in circulation on endothelial function during AS progression remains unclear. In the present study, ApoE(-/-) mice and endothelial cells line (HUVEC cells) were applied to investigate the effect of SIA on AS progression and its potential molecular mechanism. In vivo, mice were injected intraperitoneally with Neu5Ac (main form of SIA) to keep high-level SIA in circulation. ORO, H&E, and Masson staining were applied to detect the plaque progression. In vitro, HUVECs were treated with Neu5Ac at different times, CCK-8, RT-PCR, western blot, and immunoprecipitation methods were used to analyze its effects on endothelial function and the potential involved mechanism. Results from the present study showed that high plasma levels of Neu5Ac in ApoE(-/-) mice could aggravate the plaque areas as well as increase necrotic core areas and collagen fiber contents. Remarkably, Neu5Ac levels in circulation displayed a positive correlation with AS plaque areas. Furthermore, results from HUVECs showed that Neu5Ac inhibited cells viability in a time/dose-dependent manner, by then induced the activation of inflammation makers such as ICAM-1 and IL-1 beta. Mechanism study showed that the activation of excessive autophagy medicated by SQSTM1/p62 displayed an important role in endothelium inflammatory injury. Neu5Ac could modify SQSTM1/p62 as a sialylation protein, and then increase its level with ubiquitin binding, further inducing ubiquitination degradation and being involved in the excessive autophagy pathway. Inhibition of sialylation by P-3Fax-Neu5Ac, a sialyltransferase inhibitor, reduced the binding of SQSTM1/p62 to ubiquitin. Together, these findings indicated that Neu5Ac increased SQSTM1/p62-ubiquitin binding through sialylation modification, thereby inducing excessive autophagy and subsequent endothelial injury. Inhibition of SQSTM1/p62 sialylation might be a potential strategy for preventing such disease with high levels of Neu5Ac in circulation.
- 30 June 2023
- Published by Elsevier in Cellular Signalling
- Vol. 109, 110790
Oscillatory shear stress-mediated aberrant O-GlcNAc SIRT3 accelerates glycocalyx inflammatory injury via LKB1/p47phox/Hyal2 signaling
- 30 June 2023
- Published by Elsevier in Cellular Signalling
- Vol. 109, 110790
Oscillatory shear stress-mediated aberrant O-GlcNAc SIRT3 accelerates glycocalyx inflammatory injury via LKB1/p47phox/Hyal2 signaling
- Top Cited PapersOpen Access
- 1 January 2023
- Published by Ivyspring International Publisher in Theranostics
- Vol. 13 (14) , 4993-5016
Metabolite Neu5Ac triggers SLC3A2 degradation promoting vascular endothelial ferroptosis and aggravates atherosclerosis progression in ApoE-/-mice
Background: Atherosclerosis (AS) is still the major cause of cardiovascular disease (CVD) as well as stroke. Endothelial metabolic disorder has been found to be activated and then promote endothelial cells (ECs) injury, which is regarded to initiate AS progression. N-acetylneuraminic acid (Neu5Ac), a metabolite produced by hexosamine-sialic acid pathway branching from glucose metabolism, was presented as a notable biomarker of CVD and is positively correlated with ECs function. However, few studies explain whether Neu5Ac regulate AS progression by affecting EC function as well as its involved mechanisms are still unknown.
- 1 January 2023
- Published by Ivyspring International Publisher in Theranostics
- Vol. 13 (14) , 4993-5016
Top Cited PapersOpen AccessMetabolite Neu5Ac triggers SLC3A2 degradation promoting vascular endothelial ferroptosis and aggravates atherosclerosis progression in ApoE-/-mice
Background: Atherosclerosis (AS) is still the major cause of cardiovascular disease (CVD) as well as stroke. Endothelial metabolic disorder has been found to be activated and then promote endothelial cells (ECs) injury, which is regarded to initiate AS progression. N-acetylneuraminic acid (Neu5Ac), a metabolite produced by hexosamine-sialic acid pathway branching from glucose metabolism, was presented as a notable biomarker of CVD and is positively correlated with ECs function. However, few studies explain whether Neu5Ac regulate AS progression by affecting EC function as well as its involved mechanisms are still unknown.
- Open Access
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 377
Abstract 377: Evaluating delivery of TFR1-targeting therapies to the CNS in a novel humanized TFR1 mouse model
Transferrin receptor protein 1 (TFR1), also known as CD71, is a cell surface receptor that plays a major role in cellular iron uptake via receptor-mediated endocytosis. In mammalian species, this receptor is required for erythropoiesis and neural development. The efficient cellular uptake properties of TFR1 have been exploited for site-specific delivery of anti-cancer drugs and biologics, as well as targeted delivery of therapeutic genes to malignant cells overexpressing TFR1. Such delivery is achieved by several methods, including chemical conjugation of transferrin with therapeutic agents, genetic fusion of transferrin with peptides, and anti-TFR1 antibodies. Delivery of therapeutics cross the blood-brain barrier to the central nervous system (CNS) is also greatly facilitated by targeting the TFR1. At Biocytogen, we have successfully generated a humanized B-hTFR1 mouse model for evaluating TFR1-targeted therapeutics in preclinical studies. In this model, the exons 4-19 of mouse Tfr1 gene that encode the extracellular domain of the receptor were replaced by its human counterparts. As the result of this engineering, the ectodomain of the TFR1 is humanized while intracellular domain remains unchanged, maintaining the receptor’s signaling function in mice. Surface staining of erythroid cells from B-hTFR1 mice showed high levels of expression of humanized TFR1. In addition, we were able to detect anti-human TFR1 bispecific antibodies in brain tissues of the B-hTFR1 mouse after intravenous administration of the antibodies, suggesting a robust uptake of the antibodies via the hTFR1 receptor. These results indicate that the B-hTFR1 mouse model is a powerful preclinical tool to evaluate the delivery of therapeutics to the CNS in vivo. Citation Format: Chang Liu, Chengzhang Shang, Limei Ma, Xiaofei Zhou, Chaoshe Guo. Evaluating delivery of TFR1-targeting therapies to the CNS in a novel humanized TFR1 mouse model [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 377.
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 377
Open AccessAbstract 377: Evaluating delivery of TFR1-targeting therapies to the CNS in a novel humanized TFR1 mouse model
Transferrin receptor protein 1 (TFR1), also known as CD71, is a cell surface receptor that plays a major role in cellular iron uptake via receptor-mediated endocytosis. In mammalian species, this receptor is required for erythropoiesis and neural development. The efficient cellular uptake properties of TFR1 have been exploited for site-specific delivery of anti-cancer drugs and biologics, as well as targeted delivery of therapeutic genes to malignant cells overexpressing TFR1. Such delivery is achieved by several methods, including chemical conjugation of transferrin with therapeutic agents, genetic fusion of transferrin with peptides, and anti-TFR1 antibodies. Delivery of therapeutics cross the blood-brain barrier to the central nervous system (CNS) is also greatly facilitated by targeting the TFR1. At Biocytogen, we have successfully generated a humanized B-hTFR1 mouse model for evaluating TFR1-targeted therapeutics in preclinical studies. In this model, the exons 4-19 of mouse Tfr1 gene that encode the extracellular domain of the receptor were replaced by its human counterparts. As the result of this engineering, the ectodomain of the TFR1 is humanized while intracellular domain remains unchanged, maintaining the receptor’s signaling function in mice. Surface staining of erythroid cells from B-hTFR1 mice showed high levels of expression of humanized TFR1. In addition, we were able to detect anti-human TFR1 bispecific antibodies in brain tissues of the B-hTFR1 mouse after intravenous administration of the antibodies, suggesting a robust uptake of the antibodies via the hTFR1 receptor. These results indicate that the B-hTFR1 mouse model is a powerful preclinical tool to evaluate the delivery of therapeutics to the CNS in vivo. Citation Format: Chang Liu, Chengzhang Shang, Limei Ma, Xiaofei Zhou, Chaoshe Guo. Evaluating delivery of TFR1-targeting therapies to the CNS in a novel humanized TFR1 mouse model [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 377.
- Open Access
- 3 January 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12, 791841
Tetramethylpyrazine Alleviates Endothelial Glycocalyx Degradation and Promotes Glycocalyx Restoration via TLR4/NF-κB/HPSE1 Signaling Pathway During Inflammation
Tetramethylpyrazine (TMP), a Chinese traditional herbal extraction widely used in treating cardiovascular diseases, could attenuate vascular endothelial injuries, but the underlying mechanism remains incomprehensive. Vascular glycocalyx coating on the endothelium would be damaged and caused endothelial dysfunction in the inflammatory microenvironment, which was the initial factor of morbidity of many vascular diseases, such as atherosclerosis (AS). Here, we thoroughly investigated the molecular mechanism of TMP on vascular endothelial glycocalyx in the LPS-induced inflammatory model both in vitro and in vivo. Results showed that pretreatment with TMP significantly inhibited glycocalyx degradation and monocytes adhesion to the endothelial process. Moreover, TMP pretreatment inhibited the expression of HPSE1 (a major degrading enzyme of endothelial glycocalyx), Toll-like receptor 4 (TLR4), and the translocation of nuclear factor kappa B p65 (NF-κB p65). We were utilized withTLR4 siRNA, NF-κB inhibitor, and HPSE1 overexpression analysis confirmed TMP’s protection on endothelial glycocalyx injury, which further contributed to the monocyte-endothelial adhesion process. It was indicated that TMP might suppress glycocalyx degradation through TLR4/NF-κB/HPSE1 signaling pathway. Taken together, our results enriched the occurrence molecular mechanism of glycocalyx shedding and molecular regulation mechanism of TMP in protecting integrity of the glycocalyx structure during inflammation. As TMP is currently used in clinical applications, it may be considered a novel strategy against atherosclerosis through its ability to protect endothelial glycocalyx.
- 3 January 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12, 791841
Open AccessTetramethylpyrazine Alleviates Endothelial Glycocalyx Degradation and Promotes Glycocalyx Restoration via TLR4/NF-κB/HPSE1 Signaling Pathway During Inflammation
Tetramethylpyrazine (TMP), a Chinese traditional herbal extraction widely used in treating cardiovascular diseases, could attenuate vascular endothelial injuries, but the underlying mechanism remains incomprehensive. Vascular glycocalyx coating on the endothelium would be damaged and caused endothelial dysfunction in the inflammatory microenvironment, which was the initial factor of morbidity of many vascular diseases, such as atherosclerosis (AS). Here, we thoroughly investigated the molecular mechanism of TMP on vascular endothelial glycocalyx in the LPS-induced inflammatory model both in vitro and in vivo. Results showed that pretreatment with TMP significantly inhibited glycocalyx degradation and monocytes adhesion to the endothelial process. Moreover, TMP pretreatment inhibited the expression of HPSE1 (a major degrading enzyme of endothelial glycocalyx), Toll-like receptor 4 (TLR4), and the translocation of nuclear factor kappa B p65 (NF-κB p65). We were utilized withTLR4 siRNA, NF-κB inhibitor, and HPSE1 overexpression analysis confirmed TMP’s protection on endothelial glycocalyx injury, which further contributed to the monocyte-endothelial adhesion process. It was indicated that TMP might suppress glycocalyx degradation through TLR4/NF-κB/HPSE1 signaling pathway. Taken together, our results enriched the occurrence molecular mechanism of glycocalyx shedding and molecular regulation mechanism of TMP in protecting integrity of the glycocalyx structure during inflammation. As TMP is currently used in clinical applications, it may be considered a novel strategy against atherosclerosis through its ability to protect endothelial glycocalyx.
- 2 April 2020
- Published by Taylor & Francis in Xenobiotica
- Vol. 50 (8) , 939-946
Osthole inhibited the activity of CYP2C9 in human liver microsomes and influenced indomethacin pharmacokinetics in rats
Osthol, a pharmacologically active ingredient in various traditional Chinese medicines, is predominantly metabolized by CYP2C9. It may be co-administered with other drugs which are metabolized by C...
- 2 April 2020
- Published by Taylor & Francis in Xenobiotica
- Vol. 50 (8) , 939-946
Osthole inhibited the activity of CYP2C9 in human liver microsomes and influenced indomethacin pharmacokinetics in rats
Osthol, a pharmacologically active ingredient in various traditional Chinese medicines, is predominantly metabolized by CYP2C9. It may be co-administered with other drugs which are metabolized by C...